Generic Tradjenta Availability
Tradjenta is a brand name of linagliptin, approved by the FDA in the following formulation(s):
TRADJENTA (linagliptin - tablet; oral)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: May 2, 2011
Strength(s): 5MG [RLD]
Has a generic version of Tradjenta been approved?
No. There is currently no therapeutically equivalent version of Tradjenta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tradjenta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Patent 6,303,661
Issued: October 16, 2001
Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
Assignee(s): Probiodrug
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.Patent expiration dates:- April 24, 2017✓
- April 24, 2017✓
- April 24, 2017
-
Method of regulating glucose metabolism, and reagents related thereto
Patent 6,890,898
Issued: May 10, 2005
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College 1149336 Ontario Inc. New England Medical Center Hospitals, Inc.
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Patent expiration dates:- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019
-
Method of regulating glucose metabolism, and reagents related thereto
Patent 7,078,381
Issued: July 18, 2006
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.Patent expiration dates:- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7,407,955
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Patent expiration dates:- August 12, 2023✓✓
- August 12, 2023
-
Method of regulating glucose metabolism, and reagents related thereto
Patent 7,459,428
Issued: December 2, 2008
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College New England Medical Center Hospitals, Inc. 1149336 Ontario, Inc.
One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.Patent expiration dates:- February 2, 2019✓
- February 2, 2019✓
- February 2, 2019
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 8,119,648
Issued: February 21, 2012
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Patent expiration dates:- August 12, 2023✓
- August 12, 2023✓
- August 12, 2023
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 8,178,541
Issued: May 15, 2012
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Patent expiration dates:- August 12, 2023✓
- August 12, 2023✓
- August 12, 2023✓
- August 12, 2023✓
- August 12, 2023
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 13, 2015 - LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- August 13, 2015 - LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- May 2, 2016 - NEW CHEMICAL ENTITY
See also...
- Tradjenta Consumer Information (Drugs.com)
- Tradjenta Consumer Information (Wolters Kluwer)
- Tradjenta Consumer Information (Cerner Multum)
- Tradjenta Advanced Consumer Information (Micromedex)
- Tradjenta AHFS DI Monographs (ASHP)
- Linagliptin Consumer Information (Wolters Kluwer)
- Linagliptin Consumer Information (Cerner Multum)
- Linagliptin Advanced Consumer Information (Micromedex)
- Linagliptin AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
